GSK's Armala could rival Pfizer's Sutent in kidney cancer
This article was originally published in Scrip
Executive Summary
Strong first Phase III data for GlaxoSmithKline's new oral anti-angiogenic anticancer, Armala (pazopanib), recently presented at the ASCO meeting in Orlando, Florida,suggested that the drug could in future rival Pfizer's Sutent (sunitinib) in treating advanced renal cell carcinoma (RCC).